SOPHiA GENETICS SA Files 6-K for Q1 2025

Ticker: SOPH · Form: 6-K · Filed: 2025-05-06T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 6-k, registration-statement

TL;DR

SOPHIA GENETICS filed a 6-K for Q1 2025, incorporating into F-3 filings.

AI Summary

SOPHiA GENETICS SA filed a Form 6-K on May 6, 2025, for the period ending March 31, 2025. This report is incorporated by reference into their existing F-3 registration statements (333-266704 and 333-280060). The company is a foreign private issuer based in Rolle, Switzerland.

Why It Matters

This filing updates the SEC on the company's status and incorporates information into existing registration statements, which can be relevant for investors tracking ongoing disclosures.

Risk Assessment

Risk Level: low — This is a routine periodic filing (6-K) that incorporates previous information and does not appear to contain new material financial or operational updates.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of May 2025, and is deemed to be incorporated by reference into the registrant's Form F-3 registration statements.

What is the reporting period for this filing?

The conformed period of report is March 31, 2025.

When was this filing submitted to the SEC?

This filing was submitted on May 6, 2025.

Where is SOPHiA GENETICS SA's principal executive office located?

The principal executive office is located at La Pièce 12 CH-1180 Rolle, Switzerland.

Which registration statements does this filing get incorporated into?

This filing is incorporated by reference into the registration statements on Form F-3 (Registration No. 333-266704 and Registration No. 333-280060) of SOPHiA GENETICS SA.

From the Filing

0001840706-25-000011.txt : 20250506 0001840706-25-000011.hdr.sgml : 20250506 20250506070334 ACCESSION NUMBER: 0001840706-25-000011 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOPHiA GENETICS SA CENTRAL INDEX KEY: 0001840706 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] ORGANIZATION NAME: 06 Technology EIN: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40627 FILM NUMBER: 25915184 BUSINESS ADDRESS: STREET 1: LA PIECE, CH-1180 CITY: ROLLE STATE: V8 ZIP: 00000 BUSINESS PHONE: 41 21 694 10 60 MAIL ADDRESS: STREET 1: LA PIECE, CH-1180 CITY: ROLLE STATE: V8 ZIP: 00000 6-K 1 q12025sophiageneticssa6-k.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. ____________________________________ Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F SIGNATURE This Report on Form 6-K (other than Exhibit 99.3 hereto), including Exhibits 99.1 and 99.2 hereto, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration No. 333-266704&#59; Registration No. 333-280060) of SOPHiA GENETICS SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SOPHiA GENETICS SA Date: May 6, 2025 By: /s/ Daan van Well Name: Daan van Well Title: Chief Legal and Compliance Officer EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2025 99.2 Management’s discussion and analysis of financial condition and results of operations 99.3 Press release dated M ay 6 , 2025 EX-99.1 2 sophiageneticssaex991q12025.htm EX-99.1 Document Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F- 2 – Unaudited Interim Condensed Consolidated Statement s of Loss F- 3 – Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F- 4 – Unaudited Interim Condensed Consolidated Balance Sheets F- 5 – Unaudited Interim Condensed Consolidated Statements of Changes in Equity F- 6 – Unaudited Interim Condensed Consolidated Statements of Cash Flows F- 7 – Notes to the Unaudited Interim Condensed Consolidated Financial Statements F- 8 F-1 Table of Conten t s SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements F-2 Table of Conten t s SOPHiA GENETICS SA Interim Condensed Consolidated Statements of Loss (Amounts in USD thousands, except per share data) (Unaudited) Three months ended March 31, Notes      2025 2024 Revenue 5 $ 17,779   $ 15,779   Cost of revenue (5,571) (5,374) Gross profit 12,208   10,405   Research and development costs (9,118) (9,391) Selling and marketing costs (7,534) (6,951) General and administrative costs (11,600) (12,825) Other operating income, net 8  6  Operating loss (16,036) (18,756) Interest income 450  901  Interest expense (659) (143) Fair value adjustments o

View on Read The Filing